What Patients Should Know About Expanding Options in Bladder Cancer
New therapies for non-muscle invasive bladder cancer have expanded treatment options, but high costs limit accessibility. Patients must work with their care team to make informed decisions about their treatment.
The treatment landscape for bladder cancer is rapidly evolving, with five new therapies approved for non-muscle invasive disease in the last six years. Dr. Charles Peyton, an associate professor at the University of Alabama at Birmingham, emphasizes the importance of patient education and personalized care in navigating these new options. The high cost of these therapies limits their availability, making it essential for patients to research and discuss their options with their care team. Urologists are often more familiar with these treatments, which are often administered directly into the bladder. Patients with advanced disease require nuanced discussions with their care team to determine the best course of treatment. The key to effective treatment is tailoring therapy to the individual patient's needs and disease biology.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.